Ebvaciclib(PF-06873600)

立即咨询

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:	2185857-97-8
规格:	≥98%

包装与价格：

包装	价格(元)
5mg	询价
10mg	询价
25mg	询价
50mg	询价
100mg	询价

理化性质和储存条件

	Name: PF-06873600 CAS#: 2185857-97-8 Chemical Formula: C20H27F2N5O4S Exact Mass: 471.1752 Molecular Weight: 471.5238
Storage	-20℃ for 3 years in powder form
Storage	-80℃ for 2 years in solvent
Technical Information	Synonym: PF06873600; Ebvaciclib; PF 06873600; PF-06873600; Chemical Name: Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(difluoromethyl)-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-[[1-(methylsulfonyl)-4-piperidinyl]amino]- InChi Key: QIEKHLDZKRQLLN-FOIQADDNSA-N InChi Code: InChI=1S/C20H27F2N5O4S/c1-20(29)7-3-4-15(20)27-17-12(10-14(16(21)22)18(27)28)11-23-19(25-17)24-13-5-8-26(9-6-13)32(2,30)31/h10-11,13,15-16,29H,3-9H2,1-2H3,(H,23,24,25)/t15-,20-/m1/s1 SMILES Code: O=C1C(C(F)F)=CC2=CN=C(NC3CCN(S(=O)(C)=O)CC3)N=C2N1[C@H]4[C@](C)(O)CCC4

实验参考方法

In Vitro	PF-06873600 (PF06873600) is a novel, potent, selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK) with potential antitumor activity. It inhibits CDK2, CDK4 and CDK6 with Ki values of 0.09 nM, 0.13 nM and 0.16 nM, respectively. PF-06873600 exhibits antineoplastic activity by selectively binding to and inhibiting the activity of CDKs. Inhibition of these kinases leads to cell cycle arrest, induction of apoptosis and inhibition of tumor cell proliferation. CDKs, ATP-dependent serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation, are frequently overexpressed in tumor cells. PF-06873600 (Example 8) is an orally bioavailable, cyclin-dependent kinase (CDK) inhibitor, with potential antineoplastic activity[1]. PF-06873600 selectively targets, binds to and inhibits the activity of CDKs. Inhibition of these kinases leads to cell cycle arrest, induction of apoptosis and inhibition of tumor cell proliferation. CDKs, ATP-dependent serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation, are frequently overexpressed in tumor cells[2].
References	[1]. US 2018/0044344 A1. [2]. NCI Drug Dictionary

In Vitro

PF-06873600 (PF06873600) is a novel, potent, selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK) with potential antitumor activity. It inhibits CDK2, CDK4 and CDK6 with Ki values of 0.09 nM, 0.13 nM and 0.16 nM, respectively. PF-06873600 exhibits antineoplastic activity by selectively binding to and inhibiting the activity of CDKs. Inhibition of these kinases leads to cell cycle arrest, induction of apoptosis and inhibition of tumor cell proliferation. CDKs, ATP-dependent serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation, are frequently overexpressed in tumor cells.

PF-06873600 (Example 8) is an orally bioavailable, cyclin-dependent kinase (CDK) inhibitor, with potential antineoplastic activity[1]. PF-06873600 selectively targets, binds to and inhibits the activity of CDKs. Inhibition of these kinases leads to cell cycle arrest, induction of apoptosis and inhibition of tumor cell proliferation. CDKs, ATP-dependent serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation, are frequently overexpressed in tumor cells[2].

References

[1]. US 2018/0044344 A1.

[2]. NCI Drug Dictionary